CEO Arthur Kuan buys $2.37M of CG Oncology, Inc. stock
30,000 shares at about $78.88 each, bought on the open market on Nov 18.
CG Oncology, Inc.'s chief executive officer, Arthur Kuan, bought 30,000 shares of the company's stock on the open market on Nov 18. The purchase, at an average of $78.88 a share, comes to about $2.4 million.
The purchase was made in the open market, not through an award, an option exercise or a plan. The purchase raises the insider's holding by 15%, to 228,916 shares.
The trade was reported within two business days, as Section 16 requires. It is the second insider purchase at CG Oncology, Inc. reported in the last 90 days.
The numbers below are taken from the Form 4 as filed with the SEC.
| Company | CG Oncology, Inc. (CGON) |
|---|---|
| Insider | Arthur Kuan |
| Role | CEO |
| Transaction | Open-market purchase (code P) |
| Shares | 30,000 |
| Average price | $78.88 |
| Value | $2,366,425 |
| Trade date | Nov 18, 2026 |
| Filed with the SEC | Nov 18, 2026, 4:30 PM ET |
| Shares held after | 228,916 |
| Ownership | Direct |
| Rule 10b5-1 plan | Not marked in the filing |
See the detailed report on this CGON purchase
Read more CGON insider trading news · Follow CGON for the next insider trade
Source: SEC Form 4. Information only, not investment advice. Not affiliated with or endorsed by the U.S. Securities and Exchange Commission.